HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
作者： Kathleen I. Pritchard , Lois E. Shepherd , Frances P. O'Malley , Irene L. Andrulis , Dongsheng Tu
DOI: 10.1056/NEJMOA054504
关键词: Medicine 、 Oncology 、 Pathology 、 Internal medicine 、 Chemotherapy 、 Breast cancer 、 Mammary gland 、 Epirubicin 、 Methotrexate 、 Cyclophosphamide 、 Fluorouracil 、 Adjuvant
摘要: Background Amplification of the human epidermal growth factor receptor type 2 (HER2, also called HER2/neu) gene and overexpression its product in breast-cancer cells may be associated with responsiveness to anthracycline-containing chemotherapy regimens. Methods In randomized, controlled Mammary.5 trial, we studied 639 formalin-fixed paraffin-embedded specimens obtained from 710 premenopausal women node-positive breast cancer who had received either cyclophosphamide, epirubicin, fluorouracil (CEF) or methotrexate, (CMF) as adjuvant chemotherapy. HER2 amplification was evaluated use fluorescence situ hybridization, immunohistochemical analysis, polymerase-chain-reaction analysis. Results a poor prognosis regardless treatment. patients whose tumors showed HER2, CEF superior CMF when assessed on basis relapse-free survival (hazard r...
utoronto.ca
sci-hub.se 参考文章(34)
B A Gusterson, R D Gelber, A Goldhirsch, K N Price, J Säve-Söderborgh, R Anbazhagan, J Styles, C M Rudenstam, R Golouh, R Reed, Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. Journal of Clinical Oncology. ,vol. 10, pp. 1049- 1056 ,(1992) , 10.1200/JCO.1992.10.7.1049
M N Levine, V H Bramwell, K I Pritchard, B D Norris, L E Shepherd, H Abu-Zahra, B Findlay, D Warr, D Bowman, J Myles, A Arnold, T Vandenberg, R MacKenzie, J Robert, J Ottaway, M Burnell, C K Williams, D Tu, Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. ,vol. 16, pp. 2651- 2658 ,(1998) , 10.1200/JCO.1998.16.8.2651
P C Clahsen, C J van de Velde, C Duval, C Pallud, A M Mandard, A Delobelle-Deroide, L van den Broek, T M Sahmoud, M J van de Vijver, p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. Journal of Clinical Oncology. ,vol. 16, pp. 470- 479 ,(1998) , 10.1200/JCO.1998.16.2.470
A Moliterni, G Bonadonna, P Valagussa, L Ferrari, M Zambetti, Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. Journal of Clinical Oncology. ,vol. 9, pp. 1124- 1130 ,(1991) , 10.1200/JCO.1991.9.7.1124
D C Allred, G M Clark, A K Tandon, R Molina, D C Tormey, C K Osborne, K W Gilchrist, E G Mansour, M Abeloff, L Eudey, HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. Journal of Clinical Oncology. ,vol. 10, pp. 599- 605 ,(1992) , 10.1200/JCO.1992.10.4.599
Sjoerd Rodenhuis, Marijke Bontenbal, Louk V.A.M. Beex, John Wagstaff, Dick J. Richel, Marianne A. Nooij, Emile E. Voest, Pierre Hupperets, Harm van Tinteren, Hans L. Peterse, Elisabeth M. TenVergert, Elisabeth G.E. de Vries, High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer The New England Journal of Medicine. ,vol. 349, pp. 7- 16 ,(2003) , 10.1056/NEJMOA022794
Ann D. Thor, Donald A. Berry, Daniel R. Budman, Hyman B. Muss, Timothy Kute, I. Craig Henderson, Maurice Barcos, Constance Cirrincione, Susan Edgerton, Craig Allred, Larry Norton, Edison T. Liu, erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer Journal of the National Cancer Institute. ,vol. 90, pp. 1346- 1360 ,(1998) , 10.1093/JNCI/90.18.1346
R. Elledge, S. A. W. Fuqua, R. W. Brown, G. C. Chamness, C. K. Osborne, W. L. McGuire, D. C. Allred, G. M. Clark, Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer Journal of the National Cancer Institute. ,vol. 85, pp. 200- 206 ,(1993) , 10.1093/JNCI/85.3.200
Mark N. Levine, Vivien Bramwell, Kathleen Pritchard, Danielle Perrault, Brian Findlay, Hakam Abu-Zahra, David Warr, Andrew Arnold, Jamie Skillings, A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. European Journal of Cancer. ,vol. 29, pp. 37- 43 ,(1993) , 10.1016/0959-8049(93)90573-X
Mark D Pegram, Richard S Finn, Karo Arzoo, Malgorzata Beryt, Richard J Pietras, Dennis J Slamon, The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. ,vol. 15, pp. 537- 547 ,(1997) , 10.1038/SJ.ONC.1201222